Cargando…
Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555385/ https://www.ncbi.nlm.nih.gov/pubmed/33630056 http://dx.doi.org/10.1182/blood.2021010665 |
| _version_ | 1784591967523438592 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8555385 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85553852021-11-02 Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037. Blood Errata American Society of Hematology 2021-02-25 /pmc/articles/PMC8555385/ /pubmed/33630056 http://dx.doi.org/10.1182/blood.2021010665 Text en © 2021 by The American Society of Hematology This article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
| spellingShingle | Errata Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037. |
| title | Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037. |
| title_full | Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037. |
| title_fullStr | Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037. |
| title_full_unstemmed | Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037. |
| title_short | Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037. |
| title_sort | trotman j, opat s, gottlieb d, et al. zanubrutinib for the treatment of patients with waldenström macroglobulinemia: 3 years of follow-up. blood. 2020;136(18):2027–2037. |
| topic | Errata |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555385/ https://www.ncbi.nlm.nih.gov/pubmed/33630056 http://dx.doi.org/10.1182/blood.2021010665 |